<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04815408</url>
  </required_header>
  <id_info>
    <org_study_id>Z2HOC-01</org_study_id>
    <nct_id>NCT04815408</nct_id>
  </id_info>
  <brief_title>PD-1 Antibody Combined Neoadjuvant Chemotherapy for Ovarian Cancer</brief_title>
  <official_title>A Phase II Study of PD-1 Antibody Plus Neoadjuvant Chemotherapy for Advanced-stage Ovarian Cancer (Z2HOC-01)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Second Affiliated Hospital, School of Medicine, Zhejiang University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to validate the efficacy and safety of anti-PD-1 in&#xD;
      combination with neoadjuvant chemotherapy in women with advanced ovarian cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2021</start_date>
  <completion_date type="Anticipated">April 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival(PFS)</measure>
    <time_frame>12 months</time_frame>
    <description>12 months progression-free survival rate will be estimated, and 95% confidence intervals will be calculated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>R0 rate</measure>
    <time_frame>after interval debulking surgery for one week</time_frame>
    <description>R0 rate of IDS(interval debulking surgery) after neoadjuvant chemotherapy(after the completion of 3rd cycle)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRR</measure>
    <time_frame>3 months</time_frame>
    <description>CRR is defined as the percentage of the participants in the ITT population who have a Complete Response or Partial Response. The CRR will be assessed by a blind independent central reviewer per RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PRR</measure>
    <time_frame>3 months</time_frame>
    <description>At interval cytoreduction pathologic complete remission rate will be measured using RECIST and immune-related response criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>5 years</time_frame>
    <description>OS is defined as the time from the date of randomization until death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AEs</measure>
    <time_frame>3 months</time_frame>
    <description>Proportion of patients with grade 3 or more treatment-related adverse events(except hematologic toxicity) graded by CTCAE v5 in neoadjuvant chemotherapy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Ovarian Cancer</condition>
  <condition>Neoadjuvant Chemotherapy</condition>
  <condition>Anti-PD-1</condition>
  <condition>Neoadjuvant Immunotherapy</condition>
  <arm_group>
    <arm_group_label>NIC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neoadjuvant treatment BGB-A317 200mg q3 weeks (total 3 dosing) Chemotherapy regimen: albumin-bound paclitaxel 260mg/m2 , Carboplatin AUC 5 q3 weeks (total 3 dosing)&#xD;
Interval debulking surgery and HIPEC&#xD;
Adjuvant treatment Chemotherapy regimen: albumin-bound paclitaxel 260mg/m2 , Carboplatin AUC 5, Bevacizumab 7.5mg/kg q3 weeks (total 3 dosing)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Neoadjuvant treatment Chemotherapy regimen: albumin-bound paclitaxel 260mg/m2 , Carboplatin AUC 5 q3 weeks (total 3 dosing)&#xD;
Interval debulking surgery and HIPEC&#xD;
Adjuvant treatment Chemotherapy regimen: albumin-bound paclitaxel 260mg/m2 , Carboplatin AUC 5, Bevacizumab 7.5mg/kg q3 weeks (total 3 dosing)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BGB-A317</intervention_name>
    <description>PD-1 antibody，Tislelizumab (BGB-A317)</description>
    <arm_group_label>NIC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>albumin-bound paclitaxel 260mg/m2 , Carboplatin AUC 5</intervention_name>
    <description>albumin-bound paclitaxel 260mg/m2 , Carboplatin AUC 5</description>
    <arm_group_label>NC</arm_group_label>
    <arm_group_label>NIC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically confirmed adenocarcinoma of ovary, fallopian tube, primary peritoneum&#xD;
             (Non-mucinous adenocarcinoma)&#xD;
&#xD;
          2. Clinical stage IIIC/IV, and IIIC with Suidan CT ≥3 or Fagotti ≥8&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 ~ 2&#xD;
&#xD;
          4. Not received any immunotherapy before&#xD;
&#xD;
          5. Willing to participate in this study, and sign the informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. With other uncontrolled malignant tumors.&#xD;
&#xD;
          2. Any disease requiring systemic treatment with a corticosteroid (prednisone or&#xD;
             equivalent daily dose of &gt; 10mg) or other immunosuppressive agents during the 14 days&#xD;
             prior to randomization.The use of topical substitute steroids (daily dose ≤10mg of&#xD;
             prednisone or its equivalent) and prescription corticosteroids for short-term (≤7&#xD;
             days) prophylactic use or for the treatment of non-autoimmune conditions is&#xD;
             permitted.Has any active autoimmune disease or a history of autoimmunity.&#xD;
&#xD;
          3. A history of active autoimmune disease or autoimmune disease that may recur.Enrolment&#xD;
             was allowed for well-controlled type 1 diabetes, hypothyroidism requiring only hormone&#xD;
             replacement therapy, well-controlled celiac disease, skin conditions (such as&#xD;
             vitiligo, psoriasis, or alopecia) that did not require systemic treatment, or&#xD;
             conditions that were not expected to recede without an external cause.&#xD;
&#xD;
          4. A history of interstitial lung disease, non-infectious pneumonia, or poorly controlled&#xD;
             diseases (including pulmonary fibrosis, acute lung disease, etc.).&#xD;
&#xD;
          5. Subjects with active hepatitis B (defined as positive hepatitis B virus surface&#xD;
             antigen [HBsAg] test result and HBV-DNA test value higher than the upper limit of&#xD;
             normal value in the laboratory of the research center) or hepatitis C (defined as&#xD;
             positive hepatitis C virus surface antibody [HCSAB] test result and positive HCV-RNA&#xD;
             test result).&#xD;
&#xD;
          6. Known human immunodeficiency virus (HIV) infection (known to be HIV positive).&#xD;
&#xD;
          7. Have received live vaccine within 30 days before the first administration.This&#xD;
             includes but is not limited to the following: mumps, rubella, measles,&#xD;
             varicella/herpes zoster (varicella), yellow fever, rabies, BCG and typhoid vaccines&#xD;
             (inactivated virus vaccines are allowed).&#xD;
&#xD;
          8. With uncontrolled cardiac clinical symptoms or diseases.&#xD;
&#xD;
          9. Allergic to any drug in this program.&#xD;
&#xD;
         10. At the discretion of the Investigator, the subject has a history or current evidence&#xD;
             of any disease, treatment or laboratory anomaly that may confuse the results,&#xD;
             interfere with the participants' participation throughout the study, or is not in the&#xD;
             best interest of the participants to participate in the study.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jianwei Zhou, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Second Affiliated Hospital of Zhejiang University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhigang Zhang, MD</last_name>
    <phone>+86057189713631</phone>
    <email>zzg2011@zju.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Second Affiliated Hospital of Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhigang Zhang, MD</last_name>
      <phone>+86057189713631</phone>
      <email>zzg2011@zju.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 23, 2021</study_first_submitted>
  <study_first_submitted_qc>March 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 25, 2021</study_first_posted>
  <last_update_submitted>March 23, 2021</last_update_submitted>
  <last_update_submitted_qc>March 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

